ULURU Inc. announced interim results of a pharmacoeconomic evaluation being conducted in Europe. The pharmacoeconomic data has two components. The first component is the costs associated with using Altrazeal compared to both a conventional dry wound healing dressings and advanced moist wound dressings for an identical duration of treatment.

The second component compares the cost of using Altrazeal to conventional dry wound healing dressings and advanced moist wound dressings for the duration of treatment through wound closure. Currently, the CE Mark in Europe allows for Altrazeal to remain in place for up to 14 days. Clinical practice in this patient population resulted in Altrazeal being changed on average every 9 days.

Despite the unit cost of Altrazeal being higher than competitive dressings, the reduction in dressing changes and the associated personnel costs makes Altrazeal markedly economically preferable to conventional gauze dressings and advanced moist wound dressings including hydrocolloids, alginates, and foam dressings. The interim data comparing Altrazeal with conventional dry wound healing and advanced moist wound dressings on similar wounds for the duration of treatment through wound closure includes 43 patients treated with Altrazeal. In the patient population evaluated, compared to patients in available data bases using conventional treatments, Altrazeal demonstrated acceleration in wound healing.

When combined with the lower treatment cost associated with using Altrazeal, this generates a significant reduction in the cost to complete wound closure. The cost comparison using Altrazeal under the assumption of an identical 50 day period compared with alternative approaches.